BioCentury | Sep 15, 2014
Clinical News

DLX105 topical: Phase II data

A double-blind, placebo-controlled, Austrian and German Phase II trial in 59 patients with mild to moderate plaque psoriasis showed twice-daily topical 0.5% DLx10 5 for 4 weeks led to no significant clinical improvements. However, gene...
Items per page:
1 - 1 of 1